



Contents lists available at ScienceDirect

Journal of Biotechnology

journal homepage: www.elsevier.com/locate/jbiotec

Non-chromatographic preparative purification of enhanced green fluorescent protein

Dariusch Hekmat^{a,*}, Dominik Maslak^b, Matthias Freiherr von Roman^c, Peter Breitschwerdt^a, Christoph Ströhle^a, Alexander Vogt^a, Sonja Berensmeier^c, Dirk Weuster-Botz^a

^a Institute of Biochemical Engineering, Technische Universität München, Boltzmannstr. 15, 85748 Garching, Germany

^b Research Center for Industrial Biotechnology, Technische Universität München, Boltzmannstr. 17, 85748 Garching, Germany

^c Bioseparation Engineering Group, Technische Universität München, Boltzmannstr. 15, 85748 Garching, Germany

ARTICLE INFO

Article history:

Received 7 August 2014

Received in revised form

24 November 2014

Accepted 25 November 2014

Available online xxx

Keywords:

Clarified homogenized fermentation broth

Enhanced green fluorescent protein

Preparative crystallization

Protein purification

Stirred-tank crystallizer

Three-phase partitioning

ABSTRACT

Recombinant enhanced green fluorescent protein (eGFP) is used as a marker in numerous applications in biomedical research and diagnostics. For these applications, the macromolecule needs to be provided in a highly purified form. The conventional purification process of eGFP usually consists of multiple subsequent preparative chromatography steps. Since this procedure is costly and time-consuming, an alternative chromatography-free purification process was investigated. This process was a combination of three-phase partitioning (TPP) and preparative crystallization including an ultrafiltration/diafiltration (UF/DF) intermediate step. After the TPP step, eGFP with a purity level suitable for preparative crystallization of 82.5–85.0% and a yield of 84–92% was obtained depending on the scale. After cross-flow UF/DF, the crystallization was performed in parallelized mL-scale stirred tanks. A favorable robust crystal morphology was obtained combined with fast crystallization kinetics when two polyethylenglycols and ethanol were used simultaneously as crystallization additives. The crystallization process can easily be scaled-up to obtain large amounts of highly purified, concentrated eGFP with a purity >99% after a crystal wash step and resolubilization. The proposed chromatography-free purification procedure gives reason to expect significant reductions of costs and required process time compared to conventional preparative chromatography.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Green fluorescent protein (GFP) was originally discovered in 1961 while purifying the bioluminescent protein aquorin from the jellyfish *Aequorea* (Shimomura et al., 1962). GFP has proven to be a valuable tool for widespread applications in biomedical research. GFP can be passively applied as e.g. a reporter gene, cell marker, or fusion tag, and can be actively applied as an indicator for e.g. protease action, transcription factor dimerization, or Ca²⁺-sensitivity (Tsien, 1998). GFP is particularly suited as a marker for gene expression and localization of proteins in living organisms since its fluorescence intensity is not influenced by exogenous substrates and cofactors (Chalfie et al., 1994; Misteli and Spector, 1997). Purified GFP was characterized based on X-ray diffraction analyses of its crystals. The purification procedure prior to

crystallization consisted typically of multiple chromatography steps (Deschamps et al., 1995). Purified GFP was first crystallized by Morise et al. (1974). Perozzo et al. (1988) crystallized GFP for X-ray diffraction analysis using vapor diffusion techniques (McPherson, 1982). A recombinant GFP (S65T) mutant expressed in *Escherichia coli* was reported by Heim et al. (1995) which showed a four- to six-fold increase in amplitudes of single excitation peaks compared to the wild type. This protein and other mutants were later called enhanced green fluorescent protein (eGFP).

Due to the use of eGFP in above mentioned biomedical applications, the protein needs to be available in a highly purified form, preferably >99% purity, in larger amounts. In order to achieve the high level of purity, several sequential preparative packed-bed chromatography procedures are usually applied after homogenization and clarification of the fermentation broth. However, the chromatography procedures are known to have low purification capacities, to be time-consuming, and costly. Therefore, non-chromatographic alternatives were sought or combinations of preparative chromatography and non-chromatographic methods

* Corresponding author. Tel.: +49 89 289 15770; fax: +49 89 289 15714.
E-mail address: hekmat@lrz.tum.de (D. Hekmat).

60 were investigated in order to reduce the number of chromatog-
61 raphy steps. In this context, purification by aqueous two-phase
62 extraction with polyethylene glycol (PEG)/salt followed by pre-
63 cipitation by Zn^{2+} (Jain et al., 2004a) and purification by aqueous
64 two-phase extraction with PEG/Na-polyacrylate was reported
65 (Johansson et al., 2008). Another non-chromatographic purifica-
66 tion alternative is three-phase partitioning (TPP) which has been
67 successfully applied to numerous proteins (Pike and Dennison,
68 1989; Dennison and Lovrien, 1997; Przybycien et al., 2004; Ward,
69 2009; Ward and Swiatek, 2009). This procedure is typically applied
70 as an early step in downstream processing after broth homogen-
71 ization and clarification. Due to the extraordinary stability of
72 GFP, this method involving salting-out using ammonium sulfate
73 in combination with solvent precipitation using *t*-butanol is appli-
74 cable without difficulty as reported in literature (Jain et al., 2004b).
75 The combination of TPP followed by hydrophobic interaction chroma-
76 tography was described by Vessoni Penna et al. (2003, 2004,
77 2005).

78 However, the aim of obtaining a high final purity >99% was not
79 met in the above mentioned literature. On the other hand, it was
80 shown that preparative crystallization in combination with a simple
81 appropriate preceding purification step can lead to proteins
82 with the desired high purity in short processing times at high yields
83 (Hebel et al., 2013a; Smejkal et al., 2013a). It was further shown
84 previously that the preparative crystallization step in stirred-tank
85 crystallizers was easily scalable from the mL-scale to the L-scale
86 (Hebel et al., 2013b; Smejkal et al., 2013b). As to the knowledge of
87 the authors, preparative crystallization as an alternative purifica-
88 tion step of eGFP in stirred tanks was not reported in literature so
89 far. Hence, the aims of the present work were: (i) apply TPP as pre-
90 ceding step to purify an eGFP mutant to a level which is expected
91 to be appropriate for crystallization and perform an intermediate
92 ultrafiltration/diafiltration (UF/DF) step, (ii) perform non-agitated
93 μ L-scale vapor diffusion and micro-batch crystallization experi-
94 ments of the eGFP mutant based on the conditions from the above
95 described literature, and (iii) transfer the obtained experience to
96 the stirred mL-scale as described by Hekmat et al. (2007) and inves-
97 tigate the preparative crystallization step in these scalable mL-scale
98 stirred-tank crystallizers. This work describes the development of
99 a novel purification process. It was not the aim to demonstrate the
100 production of purified eGFP as a stand-alone product.

101 2. Materials and methods

102 2.1. Batch production of eGFP and protein assays

103 The eGFP used had two point mutations (F64S, S65T) with a
104 6xHis-tag attached directly to the N-terminus without spacer. The
105 total number of amino acids was 244, the molecular weight was
106 27.66 kDa, and the theoretical pI was 6.0. Data on the solubility and
107 other thermodynamic properties were not available. This protein
108 was overexpressed in *E. coli* BL21(DE3) (pQE vector backbone, T5
109 promoter) which was cultivated in a 50 L stirred-tank bioreactor
110 (Bioengineering AG, Wald, Switzerland) using an auto-induction
111 medium containing 5 g L^{-1} lactose (Riesenberger et al., 1991). Batch
112 cultivation was at $T = 37^\circ\text{C}$ and the pH was controlled at 6.8 using
113 a 25% NH_4OH -solution. The fermentation broth was homogenized
114 directly by three passages with intermediate cooling using a high
115 pressure homogenizer type Ariete NS3015 (GEA Niro Soavi, Parma
116 Italy) at 800 bar. The flow rate was 150 L h^{-1} and the temperature
117 was controlled in order not to exceed 30°C . The homogenized solu-
118 tion was then clarified batch-wise at room temperature using a
119 floor-standing centrifuge type Rotixa 50 RS with a nominal capac-
120 ity of $4 \text{ L} \times 1 \text{ L}$ at $4000 \times g$ for 10 min (Andreas Hettich GmbH &
121 Co. KG, Tuttlingen, Germany). The total protein concentration of

122 the solutions was measured by Bradford assay (Bradford, 1976).
123 The concentration of the eGFP was measured by fluorescence assay
124 (Elslinger et al., 1999). The excitation wavelength was 485 nm, the
125 emission wavelength was 515 nm. The pH dependency of the fluo-
126 rescence assay was accounted for in the data analysis by calibrating
127 at two different pH levels of pH 6.5 and pH 8.0. Both assays were
128 performed in a 96-well microplate reader type Tecan Infinite M200
129 (Tecan Group AG, Männedorf, Switzerland).

130 2.2. Purification of eGFP by immobilized metal affinity 131 chromatography, anion exchange chromatography, and size 132 exclusion chromatography

133 Purification of eGFP to >99% purity by SEC-HPLC for calibration
134 of protein assays and sitting drop crystallization screening experi-
135 ments was performed at room temperature by four consecutive
136 chromatography steps using an ÄKTA explorer 100 chromatogra-
137 phy system (GE Healthcare, Munich, Germany): (1) immobilized
138 metal affinity chromatography (IMAC), (2) first size exclusion chro-
139 matography (SEC) step, (3) anion exchange chromatography (AEX),
140 and (4) second SEC step. The initial recovery of eGFP from the
141 clarified cell homogenate was performed by IMAC using a 5 mL pre-
142 packed HisTrap FF crude column (GE Healthcare, Munich, Germany)
143 which was equilibrated with binding buffer (50 mM NaH_2PO_4 , pH
144 7.9, 500 mM NaCl) in advance. Impurities were removed using a
145 step gradient to 4% elution buffer (50 mM NaH_2PO_4 , pH 7.9, 500 mM
146 NaCl, 500 mM imidazole) and the target protein was eluted by a
147 step gradient to 100% elution buffer. Target protein containing frac-
148 tions were pooled and the buffer was subsequently exchanged for
149 AEX binding buffer (50 mM Tris pH 8.5) in a first SEC step using a
150 HiPrep 26/10 desalting column (GE Healthcare, Munich, Germany).
151 The desalted fractions containing eGFP were then loaded onto a
152 self-packed Unosphere Q column (1 cm \times 13 cm, column volume
153 10 mL, Bio-Rad Laboratories, Munich, Germany) at a flow rate of
154 2 mL min^{-1} . eGFP was eluted with help of a linear gradient from 0%
155 to 50% AEX elution buffer (50 mM Tris, pH 8.5, 1 M NaCl) over five
156 column volumes. Aggregates and further impurities were removed
157 by a second SEC step by injecting 2 mL of the AEX-purified eGFP
158 solution onto a HiLoad 16/600 Superdex 75 pg column (GE Health-
159 care, Munich, Germany) and eluting isocratically with a continuous
160 flow of crystallization buffer (50 mM Tris, pH 8.0) at a flow rate of
161 1 mL min^{-1} .

162 2.3. Purification of eGFP by three-phase partitioning and 163 hydrophobic interaction chromatography

164 The three-phase partitioning (TPP) method consisted of two
165 steps (Dennison and Lovrien, 1997). In the first step, a protein
166 solution saturated with ammonium sulfate (30% saturation) was
167 thoroughly mixed in a vortexer for 10 min with pure *t*-butanol
168 (volume ratio 1:1). After centrifugation at room temperature at
169 $4000 \times g$ for 10 min using a laboratory centrifuge type 5415 R
170 (Eppendorf Zentrifugen GmbH, Leipzig, Germany), a three-phase
171 system was formed with an upper organic phase, a semi-solid inter-
172 phase, and a lower aqueous phase. The upper phase contained
173 host cell proteins (HCP), lipids, and other hydrophobic substances.
174 The interphase consisted mainly of precipitated HCP. The lower
175 phase contained mainly dissolved eGFP and some hydrophilic HCP.
176 In the second step, the lower phase which was separated from
177 the upper phase and the interphase was again thoroughly mixed
178 with pure *t*-butanol in a vortexer for 10 min (volume ratio 1:2).
179 Again, a three-phase system was formed where the upper phase
180 consisted predominantly of *t*-butanol, the interphase was mainly
181 precipitated eGFP, and the lower phase contained hydrophilic HCP.
182 After centrifugation at $4000 \times g$ for 10 min, the upper and lower
183 phases were discarded and the precipitated eGFP was dissolved in

Download English Version:

<https://daneshyari.com/en/article/6491254>

Download Persian Version:

<https://daneshyari.com/article/6491254>

[Daneshyari.com](https://daneshyari.com)